Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EI-001 in Nonsegmental Vitiligo
NCT07223229Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of EI-001 in Vitiligo. Started Dec 2025; status: recruiting.
02
Drugs
EI-001
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07223229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223229.